The Delaware Chancery Court dismissed shareholder litigation Friday alleging Chelsea Therapeutics International Ltd.'s board acted in bad faith by omitting two projections from disclosures ahead of the drugmaker's 2014 sale, ruling the optimistic earnings forecasts were unlikely to be realized.